|Bid||87.96 x 1100|
|Ask||88.07 x 800|
|Day's range||85.61 - 88.10|
|52-week range||55.25 - 159.89|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2024 - 01 Mar 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||140.28|
Sarepta Therapeutics (NASDAQ: SRPT) is a mid-cap stock that has the potential to be a big player in the gene therapy market -- at least, so the business and its investors hope. It has made for a volatile investment in recent years, but with a possible game-changing treatment in its portfolio, there may be a ton of upside for Sarepta in the long run. With over 40 programs currently in development, Sarepta is hopeful it can become a leading genetic medicine company one day.
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.